Xintela AB (publ) (XINT.ST)
SEK 0.35
(-5.9%)
SEK 0.35
(-5.9%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 18.39 Million SEK | -24.97% |
| 2022 | 24.51 Million SEK | -0.91% |
| 2021 | 24.74 Million SEK | -49.0% |
| 2020 | 48.51 Million SEK | 183.82% |
| 2019 | 17.09 Million SEK | -65.62% |
| 2018 | 49.71 Million SEK | 73.92% |
| 2017 | 28.58 Million SEK | 19.86% |
| 2016 | 23.84 Million SEK | 124.52% |
| 2015 | 10.62 Million SEK | 1.2% |
| 2014 | 10.49 Million SEK | 48.16% |
| 2013 | 7.08 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.93 Million SEK | -50.49% |
| 2024 Q1 | 22.08 Million SEK | 20.05% |
| 2023 Q4 | 18.39 Million SEK | -11.23% |
| 2023 Q2 | 13.99 Million SEK | -17.24% |
| 2023 Q3 | 20.72 Million SEK | 48.11% |
| 2023 Q1 | 16.9 Million SEK | -31.05% |
| 2023 FY | 18.39 Million SEK | -24.97% |
| 2022 Q2 | 11.75 Million SEK | -26.66% |
| 2022 Q4 | 24.51 Million SEK | 99.85% |
| 2022 FY | 24.51 Million SEK | -0.91% |
| 2022 Q1 | 16.02 Million SEK | -35.24% |
| 2022 Q3 | 12.26 Million SEK | 4.41% |
| 2021 Q2 | 50.51 Million SEK | 45.38% |
| 2021 Q3 | 39.51 Million SEK | -21.78% |
| 2021 Q4 | 24.74 Million SEK | -37.38% |
| 2021 FY | 24.74 Million SEK | -49.0% |
| 2021 Q1 | 34.74 Million SEK | -28.38% |
| 2020 Q2 | 30.79 Million SEK | 46.06% |
| 2020 FY | 48.51 Million SEK | 183.82% |
| 2020 Q4 | 48.51 Million SEK | 34.12% |
| 2020 Q3 | 36.17 Million SEK | 17.44% |
| 2020 Q1 | 21.08 Million SEK | 23.37% |
| 2019 Q1 | 39.39 Million SEK | -20.75% |
| 2019 FY | 17.09 Million SEK | -65.62% |
| 2019 Q3 | 21.04 Million SEK | -29.24% |
| 2019 Q4 | 17.09 Million SEK | -18.79% |
| 2019 Q2 | 29.74 Million SEK | -24.5% |
| 2018 Q3 | 19.2 Million SEK | -11.44% |
| 2018 FY | 49.71 Million SEK | 73.92% |
| 2018 Q4 | 49.71 Million SEK | 158.86% |
| 2018 Q1 | 21.98 Million SEK | -23.09% |
| 2018 Q2 | 21.68 Million SEK | -1.36% |
| 2017 Q4 | 28.58 Million SEK | 59.28% |
| 2017 FY | 28.58 Million SEK | 19.86% |
| 2017 Q1 | 27.35 Million SEK | 14.68% |
| 2017 Q2 | 22.81 Million SEK | -16.6% |
| 2017 Q3 | 17.94 Million SEK | -21.33% |
| 2016 FY | 23.84 Million SEK | 124.52% |
| 2016 Q4 | 23.84 Million SEK | -11.2% |
| 2016 Q3 | 26.85 Million SEK | -13.1% |
| 2016 Q2 | 30.9 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 FY | 10.62 Million SEK | 1.2% |
| 2015 Q4 | 10.62 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | 10.49 Million SEK | 48.16% |
| 2013 FY | 7.08 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 85.068% |
| Amniotics AB (publ) | 26.08 Million SEK | 29.483% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -202.699% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.449% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.032% |
| Saniona AB (publ) | 64.14 Million SEK | 71.322% |
| Simris Alg AB (publ) | 174.55 Million SEK | 89.462% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 96.293% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -23.714% |
| NextCell Pharma AB | 81.28 Million SEK | 77.371% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 39.035% |
| AcouSort AB (publ) | 34.51 Million SEK | 46.701% |
| Active Biotech AB (publ) | 44 Million SEK | 58.193% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 84.47% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.036% |
| Cantargia AB (publ) | 223.71 Million SEK | 91.777% |
| Genovis AB (publ.) | 288.85 Million SEK | 93.632% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 78.416% |
| Mendus AB (publ) | 755.95 Million SEK | 97.567% |
| Kancera AB (publ) | 65.64 Million SEK | 71.977% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.538% |
| LIDDS AB (publ) | 17.65 Million SEK | -4.191% |
| Lipum AB (publ) | 12.11 Million SEK | -51.899% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 45.256% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 93.401% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 8.213% |
| OncoZenge AB (publ) | 20.34 Million SEK | 9.562% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 97.185% |
| Ziccum AB (publ) | 14.97 Million SEK | -22.863% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 86.917% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 97.596% |
| CombiGene AB (publ) | 120.61 Million SEK | 84.749% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 91.525% |
| Intervacc AB (publ) | 259.61 Million SEK | 92.914% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 70.51% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 56.16% |
| Corline Biomedical AB | 100.1 Million SEK | 81.624% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 89.614% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 70.403% |
| Aptahem AB (publ) | 63.02 Million SEK | 70.813% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 94.764% |
| Fluicell AB (publ) | 9.34 Million SEK | -96.949% |
| Biovica International AB (publ) | 131.4 Million SEK | 86.002% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 65.283% |
| Abliva AB (publ) | 87.49 Million SEK | 78.977% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 97.58% |
| 2cureX AB (publ) | 16.62 Million SEK | -10.647% |
| I-Tech AB | 152.44 Million SEK | 87.933% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.193% |
| Cyxone AB (publ) | 43.65 Million SEK | 57.863% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 76.624% |
| Biosergen AB | 7.2 Million SEK | -155.451% |
| Nanologica AB (publ) | 77.42 Million SEK | 76.243% |
| SynAct Pharma AB | 228.01 Million SEK | 91.933% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 31.267% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.686% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 15.242% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 92.283% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -117.564% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 78.874% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 35.474% |